2022
The Contribution of Chronic Conditions to Hospitalization, Skilled Nursing Facility Admission, and Death: Variation by Race
Quiñones AR, McAvay GJ, Peak KD, Vander Wyk B, Allore HG. The Contribution of Chronic Conditions to Hospitalization, Skilled Nursing Facility Admission, and Death: Variation by Race. American Journal Of Epidemiology 2022, 191: 2014-2025. PMID: 35932162, PMCID: PMC10144669, DOI: 10.1093/aje/kwac143.Peer-Reviewed Original ResearchConceptsSkilled nursing facility admissionsNursing facility admissionsChronic conditionsFacility admissionMedicare beneficiariesCostly health care utilizationHealth care utilizationRacial differencesNon-Hispanic blacksWhite Medicare beneficiariesAverage attributable fractionHealth-related outcomesImportant health-related outcomesNon-Hispanic White older adultsWhite older adultsAging Trends StudyMultimorbidity burdenRenal morbidityOngoing careAttributable fractionNational HealthCardiovascular conditionsOlder adultsImportant markerHospitalizationRisk Factors of Skilled Nursing Facility Admissions and the Interrelation With Hospitalization and Amount of Informal Caregiving Received
Cao Y, Allore H, Gutman R, Vander Wyk B, Jørgensen TSH. Risk Factors of Skilled Nursing Facility Admissions and the Interrelation With Hospitalization and Amount of Informal Caregiving Received. Medical Care 2022, 60: 294-301. PMID: 35149662, PMCID: PMC8916995, DOI: 10.1097/mlr.0000000000001697.Peer-Reviewed Original ResearchConceptsSkilled nursing facility admissionsNursing facility admissionsNumber of hospitalizationsSNF admissionImportant risk factorRisk factorsHospital admissionFacility admissionNon-Hispanic white race/ethnicityWhite race/ethnicityInformal caregivingWeak positive correlationDaily living (ADL) disabilityPossible risk factorsPositive correlationAging Trends StudyRace/ethnicityObservational followStrong positive correlationNational HealthAdmissionDementia diagnosisHospitalizationAlzheimer's diseaseHealth factors
2016
Methodology to Estimate the Longitudinal Average Attributable Fraction of Guideline-recommended Medications for Death in Older Adults With Multiple Chronic Conditions
Allore HG, Zhan Y, Cohen AB, Tinetti ME, Trentalange M, McAvay G. Methodology to Estimate the Longitudinal Average Attributable Fraction of Guideline-recommended Medications for Death in Older Adults With Multiple Chronic Conditions. The Journals Of Gerontology Series A 2016, 71: 1113-1116. PMID: 26748093, PMCID: PMC4945884, DOI: 10.1093/gerona/glv223.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAgedAged, 80 and overCardiovascular DiseasesDrug PrescriptionsDrug Therapy, CombinationFemaleFollow-Up StudiesHumansMaleMedicareMultiple Chronic ConditionsPractice Guidelines as TopicRetrospective StudiesSurveys and QuestionnairesSurvival RateThiazidesTreatment OutcomeUnited StatesConceptsMultiple chronic conditionsAverage attributable fractionChronic conditionsAttributable fractionCardiovascular conditionsHeart failureMedicare Current Beneficiary Survey participantsRenin-angiotensin system blockersGuideline-recommended medicationsMore chronic conditionsAge-stratified modelsSystem blockersBeta blockersCardiovascular medicationsOral medicationsAtrial fibrillationMedication effectsMedicationsAge strataParticipant characteristicsOlder adultsSurvivalThiazidesBlockersAge
2015
Association between guideline recommended drugs and death in older adults with multiple chronic conditions: population based cohort study
Tinetti ME, McAvay G, Trentalange M, Cohen AB, Allore HG. Association between guideline recommended drugs and death in older adults with multiple chronic conditions: population based cohort study. The BMJ 2015, 351: h4984. PMID: 26432468, PMCID: PMC4591503, DOI: 10.1136/bmj.h4984.Peer-Reviewed Original ResearchConceptsSerotonin-norepinephrine reuptake inhibitorsMultiple chronic conditionsSelective serotonin reuptake inhibitorsAdjusted hazard ratioRisk of deathCalcium channel blockersChronic conditionsHazard ratioΒ-blockersCohort studyReuptake inhibitorsAtrial fibrillationOlder adultsChannel blockersCardiovascular drugsSSRIs/serotonin-norepinephrine reuptake inhibitorsRenin-angiotensin system blockersNorepinephrine reuptake inhibitorsSerotonin reuptake inhibitorsCommon combinationRAS blockersSystem blockersStudy drugHeart failureThromboembolic disease